Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, New York 14642


Purpose:

RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more comfortably. PURPOSE: Clinical trial to determine the effect of androgen suppression on bone loss in patients who have prostate cancer.


Study summary:

OBJECTIVES: - Evaluate the effect of androgen ablation on bone resorption in patients with or without bone metastases secondary to prostate cancer. OUTLINE: Patients are stratified according to prior androgen ablation therapy (yes vs no) and metastatic disease (yes vs no). Patients undergo blood work and 24 hour urine collection on day 1 and at week 6-8. Patients who have received androgen ablation therapy and are found to have increased bone resorption undergo a dual energy x-ray absorptiometry (DEXA) scan. A comparison is made between androgen ablation therapy and bone resorption and if metastases are associated with the two. PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study within 9 months.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed prostate cancer - Stratum 1 (androgen ablation therapy): - Bone metastases - Prior orchiectomy allowed - Prior or concurrent leuprolide and/or goserelin therapy allowed - Stratum 2 (androgen ablation therapy): - No bone metastases - Prior orchiectomy allowed - Prior or concurrent leuprolide and/or goserelin therapy allowed - Stratum 3 (no androgen ablation therapy): - No metastatic disease - Prior flutamide or bicalutamide therapy allowed PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Calcium normal Hepatic: - Not specified Renal: - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics Endocrine therapy: - See Disease Characteristics - No concurrent high dose steroids Radiotherapy: - Prior radiotherapy allowed Surgery: - See Disease Characteristics - Prior radical prostatectomy allowed Other: - No concurrent bisphosphonates


NCT ID:

NCT00003903


Primary Contact:

Study Chair
Deepak M. Sahasrabudhe, MD
James P. Wilmot Cancer Center


Backup Contact:

N/A


Location Contact:

Rochester, New York 14642
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 11, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.